On Thursday, Shares of Incyte Corporation (NASDAQ:INCY), gained 5.33% to $124.50.
Aduro Biotech, declared that it has reached a clinical trial agreement with Incyte Corporation (INCY) to evaluate the safety, tolerability and preliminary efficacy of Aduro’s lead LADD immunotherapy, CRS-207, in combination with Incyte’s oral indoleamine dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), in patients with ovarian cancer.
The combination of both investigational immunotherapeutic agents, which have different but complementary mechanisms directed at enhancing the body’s own immune defenses, may provide unique synergies in fighting cancer. Incyte’s epacadostat has been shown in vitro and in preclinical tumor models to enhance activities of multiple types of immune cells by reducing the immune suppression characteristic of the tumor microenvironment. Aduro’s CRS-207 has been shown to stimulate immune cell activity, with particular targeting mechanisms that seek and attack tumor cells that express mesothelin like those found in ovarian cancer.
“There’s a growing body of evidence and enthusiasm in the field of oncology to combine therapeutic agents with different mechanisms that may result in very powerful approaches to treating tough cancers,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “Incyte is a leader in the field of cancer immunotherapy and we’re happy to join forces with them to study a novel approach to treating ovarian cancer.”
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), counting primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF.
Shares of Banco Bilbao Vizcaya Argentaria SA (ADR) (NYSE:BBVA), inclined 0.45% to $8.89, during its last trading session.
With investors concerned about weakened liquidity across the financial markets amid the tumult on Wall Street and a looming rate hike, BBVA Compass economists say in a new report that post-crisis regulatory environment and technological advancements have reshuffled liquidity risks from banks to large investors.
“The shifting of liquidity risk from banks to large investors has, as intended, lowered the systemic risk of regulated financial institutions but raised bond market volatility,” writes Shushanik Papanyan, BBVA Compass senior economist. “New liquidity dynamics such as a new regulatory environment and high-frequency electronic trading have created a new class of dominant players in the bond market, changed the way bonds are traded and how money is allocated.”
Businesses and governments turn to bond markets to raise debt capital through corporate, treasury and government bonds. Changes in the interest rate environment may affect bond liquidity, but the effect is only temporary and the Fed’s policy normalization will not reduce the magnitude of existing issues, the bank’s economists say in the report.
Banco Bilbao Vizcaya Argentaria, S.A. engages in the retail banking, wholesale banking, asset administration, and private banking businesses primarily in Spain, Eurasia, Mexico, South America, and the United States.
At the end of Thursday’s trade, Shares of Sabre Corp (NASDAQ:SABR), gained 0.25% to $28.53.
Sabre Corporation, declared that Rick Simonson, executive vice president and chief financial officer, plans to take part in the Deutsche Bank 2015 Technology Conference on September 16, 2015 starting at 10:20 a.m. PT/ 1:20 p.m. ET.
Sabre Corporation provides technology solutions to the travel and tourism industry worldwide. It operates in two segments: Travel Network, and Airline and Hospitality Solutions. The Travel Network segment operates a business-to-business travel marketplace that offers travel content, such as inventory, prices, and availability from a range of travel suppliers, counting airlines, hotels, car rental brands, rail carriers, cruise lines, and tour operators, with a network of travel buyers comprising online and offline travel agencies, travel administration companies, and corporate travel departments.
Finally, Nexvet Biopharma plc (NASDAQ:NVET), ended its last trade with -20.38% loss, and closed at $4.98.
Nexvet Biopharma, declared financial results for its 2015 fiscal year, which concluded on June 30th.
Corporate Highlights:
- In September 2014, the Company reorganized in the Republic of Ireland with all security holders exchanging their shares for equivalent securities in the Irish company.
- In October 2014, Nexvet initiated a pivotal field safety and efficacy study for NV-01, the Company’s monoclonal antibody (mAb) therapy in development for the control of pain associated with osteoarthritis in dogs.
- In December 2014, the Company declared the signing of a ten-year partnershipand distribution agreement with Virbac, one of the largest animal health dedicated companies in the world. Under the agreement, Virbac will distribute NV-01 outside the United States and Canada on an equal profit-sharing basis and has the right to negotiate access to future Nexvet products on a product-by-product basis for development, distribution, marketing and sales, subject to separately agreed-upon financial terms.
- In February 2015, the Company closed its initial public offering (IPO) of 4.0 million ordinary shares at a price to the public of $10.00 per share. The underwriters purchased an additional 0.2 million shares following their overallotment option. As a result of these sales, the Company received aggregate gross proceeds of $41.8 million and net proceeds of $38.0 million.
- In March 2015, the Company designated former Novartis Animal Health Division Head, Dr. George Gunn, as Chairman of the Nexvet Board of Directors.
- In April 2015, following results of a sample size reassessment of NV-01’s pivotal safety and efficacy study, Nexvet declared its plan to continue the study to completion without substantially increasing its size, while also commencing a new pilot field safety and efficacy study to assess various doses and dosing regimens of NV-01. This new study is predictable to enrol about 150 dogs, cost about $1.0 million and the Company anticipates data in the fourth quarter of 2015.
- In May 2015, the Company declared that Dr. Jurgen Horn would join Nexvet as Chief Product Development Officer, effective August 2015. Dr. Horn’s recent roles comprised Senior Director of Global Innovation Strategy at Elanco and Head of Global Pharmaceuticals Development at Novartis Animal Health.
- In June 2015, Nexvet declared positive top-line results from a proof-of-concept efficacy study and a pilot safety study of NV-02, the Company’s mAb therapy in development for the control of pain associated with degenerative joint disease (DJD), counting osteoarthritis, in cats.
Nexvet Biopharma public limited company, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel, species-specific biologics based on human biologics for companion animals.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
